Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIASTAT vs ATACAND HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Status epilepticus (FDA-approved for acute management),Breakthrough seizures in patients on stable antiepileptic regimen (FDA-approved),Preoperative anxiety (off-label),Alcohol withdrawal syndrome (off-label),Muscle spasm (off-label)
Treatment of hypertension, for patients not adequately controlled on monotherapy.
Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
30–60 hours for diazepam; nordazepam (active metabolite) 50–120 hours. Prolonged in elderly, liver disease, and neonates
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Primarily hepatic via CYP2C19 and CYP3A4; active metabolite desmethyldiazepam (with long half-life); minor pathways include glucuronidation.
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
Renal (primarily as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal minimal
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
98–99%; primarily albumin
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
0.8–1.0 L/kg; increased in obesity (1.5–2.5 L/kg), redistribution to adipose tissue prolongs half-life
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
Rectal: 90% (relative to IV, complete absorption). Oral: 100%
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
No specific dose adjustment required for renal impairment; however, use with caution in severe impairment (Cr Cl <10 m L/min) due to prolonged half-life.
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75% or avoid use.
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
Children 2-5 years: 0.5 mg/kg (max 20 mg) rectally. Children 6-11 years: 0.3 mg/kg (max 20 mg) rectally. Children 12+ years: same as adult dosing. May repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
Safety and efficacy not established in pediatric patients (<18 years).
Initiate at lower end of dosing range (e.g., 0.1-0.15 mg/kg, max 10 mg) due to increased sensitivity and risk of falls; monitor for prolonged sedation and respiratory depression.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
None.
Risk of respiratory depression, especially with concomitant CNS depressants; tolerance and physical dependence may develop; withdrawal symptoms including seizures after abrupt discontinuation; caution in elderly, debilitated patients, and those with hepatic impairment; may cause drowsiness or dizziness; not recommended for use in pregnancy (neonatal withdrawal).
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Known hypersensitivity to diazepam or any benzodiazepine; myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; narrow-angle glaucoma (in patients receiving anticholinergic therapy).
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
No specific food interactions. Avoid grapefruit juice as it may increase diazepam levels. Alcohol can potentiate CNS depression.
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal symptoms postnatally; risk of floppy infant syndrome (hypotonia, lethargy, sucking difficulties) when administered near term.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
Diazepam is excreted into breast milk with an M/P ratio of approximately 0.2-0.5. The American Academy of Pediatrics recommends use with caution due to potential accumulation and sedation in the infant. Avoid chronic use; if necessary, monitor infant for sedation, poor feeding, and weight gain.
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
Due to increased volume of distribution and altered protein binding in pregnancy, total clearance of diazepam may be increased, potentially requiring higher doses to achieve therapeutic effect. However, routine dose adjustment is not recommended without clinical monitoring. Use lowest effective dose for shortest duration. Caution in third trimester due to increased risk of neonatal effects.
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
DIASTAT (diazepam rectal gel) is a formulation for acute management of seizure clusters. Administer rectally; monitor for respiratory depression, especially with concomitant CNS depressants. Do not exceed 5 doses per month or use for more than 5 episodes per month due to tolerance risk. Have flumazenil available for reversal.
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
Use only as directed for episodes of increased seizure activity.,Administer rectally; do not reuse diapers/suppositories.,Monitor for drowsiness, dizziness, or breathing problems.,Avoid alcohol and other CNS depressants.,Store at room temperature; protect from light.,Seek emergency care if seizures last longer than usual or breathing is difficult.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIASTAT vs ATACAND HCT, answered by our medical review team.
DIASTAT is a Benzodiazepine Anticonvulsant that works by Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.. ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIASTAT and ATACAND HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIASTAT is: Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.. The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIASTAT and ATACAND HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIASTAT is classified as Category C. DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.